跳至主要内容
临床试验/CTRI/2013/10/004114
CTRI/2013/10/004114已完成1 期

Aqueous Humor Bioequivalence Study of Loteprednol 0.5 %, Sun Pharmaceutical Industries Ltd (SPIL) and Lotemax in Patients Undergoing Cataract Surgery: A Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Cross over, Active Controlled Study

Sun Pharma Advanced Research Company Ltd3 个研究点 分布在 1 个国家目标入组 62 人开始时间: 2014年10月4日最近更新:

试验速览

阶段
1 期
状态
已完成
入组人数
62
试验地点
3
主要终点
Pharmacokinetic assessment

研究概览

简要总结

The study will be conducted to assess bioequivalence of SPIL’sloteprednol ophthalmic suspension to the reference listed drug in patients undergoingcataract surgery and to monitor the safety of the patients participating in thestudy.

研究设计

研究类型
Interventional
分配方式
Computer generated randomization
盲法
Not Applicable

入排标准

年龄范围
18.00 Year(s) 至 99.00 Year(s)(—)
性别
All

入选标准

  • Men or women ≥18 years of age (no upper age limit mentioned in the protocol) -Willing to give informed consent -elected for cataract extraction.

排除标准

  • history of hypersensitivity to any of the components used in the preparation of the study drug -History of chronic or recurrent severe inflammatory eye disease.

结局指标

主要结局

Pharmacokinetic assessment

时间窗: Pre-dose, 30 min, 60 min, 90 min, 120 min, 240 min and 360 minutes

次要结局

  • Safety(Visit 2 to Visit 6)

研究者

申办方类型
Pharmaceutical industry-Indian

研究点 (3)

Loading locations...

相似试验